Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder.

ABSTRACT:

Background

Patients with overactive bladder (OAB) experience sudden, intense urges to urinate, which may include urge urinary incontinence and nocturia. Pharmacotherapy includes β₃-adrenergic receptor agonists such as mirabegron; however, mirabegron contains a label warning for cytochrome P450 (CYP) 2D6 inhibition, making coadministration with CYP2D6 substrates require monitoring and dose adjustment to avoid unintended increases in substrate concentration.

Objective

To understand the codispensing patterns of mirabegron among patients using ten predefined CYP2D6 substrates with and before mirabegron dispensing.

Methods

This retrospective claims database analysis used the IQVIA PharMetrics^® Plus Database to assess codispensing of mirabegron with te

SUBMITTER: Wang J 

PROVIDER: S-EPMC10491567 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature